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Abstract
Purpose This prospective clinical study investigates the
efficacy of a specific custom-made titratable mandibular
advancement device (MAD) for the treatment of obstructive
sleep apnea (OSA). This MAD has attachments in the front-
al teeth area that allow for progressive titration of the
mandible.
Methods Sixty-one adult OSA patients were included (age,
46.7±9.0 years; male/female ratio, 45/16; apnea–hypopnea
index (AHI), 23.2±15.4 events/h sleep; body mass index,
27.9±4.1 kg/m²). After an adaptation period, titration started
based on a protocol of symptomatic benefit or upon reach-
ing the physiological limits of protrusion. As a primary
outcome, treatment response was defined as an objective
reduction in AHI following MAD treatment of ≥50 % com-
pared to baseline, and treatment success as a reduction in
AHI with MAD to less than 5 and 10 events/h sleep. Com-
pliance failure was defined as an inability to continue
treatment.
Results A statistically significant decrease was observed in
AHI, from 23.4±15.7 at baseline to 8.9±8.6 events/h with
MAD (p<0.01). Treatment response was achieved in 42 out of
61 patients (68.8 %), whereas 42.6 % met criteria of AHI<5
and 63.9 % achieved an AHI<10 events/h sleep, respectively.
Four patients (6.6 %) were considered as “compliance
failures.”
Conclusions The present study has evaluated the efficacy of
a specific custom-made titratable MAD in terms of sleep
apnea reduction.
Keywords Snoring . Sleep-disordered breathing . Daytime
sleepiness . Mandibular repositioning appliance
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Introduction
Obstructive sleep apnea (OSA) is a highly prevalent public
health issue affecting an estimated 2 % of middle-aged
women and 4 % of middle-aged men [1]. OSA is character-
ized by recurrent apneas or hypopneas during sleep, resulting in
hypoxemia, arousal from sleep, and sleep fragmentation [2, 3].
OSA is an independent risk factor for cardiovascular complica-
tions and can be associated with a relatively high morbidity and
mortality [1, 4, 5]. Continuous positive airway pressure (CPAP)
is regarded as the gold standard treatment for OSA [6]. How-
ever, despite its high therapeutic efficacy, it is not always well
tolerated by patients, resulting in a limited clinical effective-
ness [7, 8]. Oral appliances are considered a noninvasive
treatment option for patients with mild to moderate sleep apnea
and for patients who do not comply with or refuse CPAP
treatment [9, 10]. Mandibular advancement devices (MADs),
worn intraorally at night in order to advance the mandible and
to reduce the collapsibility of the upper airway, are the most
common class of oral appliances used to treat OSA [8, 10–12].
MAD therapy has been shown to reduce the severity of OSA to
a lesser or similar degree than CPAP [8, 13–15]. Currently,
there is growing evidence that both CPAP and MADs have a
beneficial effect on OSA-related adverse health consequences
like cardiovascular morbidity [4, 14, 16–18].
There is a huge variety of commercially available MADs
each with its particular concept [12, 19, 20]. Oral appliance
design has been suggested as one of the factors that will affect
treatment success, adherence, and side effects [19, 20]. Prefab-
ricated MADs are made out of thermoplastic material, the
“boil-and-bite devices”, and can be fitted chair-sided, prefera-
bly by a dental sleep professional at the outpatient clinic.
However, research showed that this type of MADs has limited
effectiveness [12, 21, 22]. Custom-made MADs are made in a
dental technical lab from individual impressions of a patient’s
tooth arches [11, 21]. It is found that custom-made MADs are
better tolerated and provide a higher efficacy compared to
thermoplastic appliances [16, 21]. The MAD was originally
available as a “monobloc” type with the upper and lower parts
statically connected and has evolved into the current “duobloc”
or “titratable” generation with separate upper and lower parts
that are dynamically interconnected. This allows for gradual
forward positioning of the mandible until the optimal mandib-
ular position is reached within the patients’ physiological
protrusive limits. This gradual positioning of the mandible,
called the titration process, is a straightforward mechanism,
but the procedure is complex because of the lack of a gold
standard method [23]. Titratable MADs allow for easy protru-
sive changes without the need for corrective work in the dental
laboratory as is generally the case with the monobloc MAD
that should require additional protrusive adjustment.
Last generation MADs can be divided in a group of
devices that cover all teeth in the upper and lower jaw versus
a group that relies on selective embracement of tooth arc
areas. The MAD used in this study belongs to the latter
group, consisting of an upper and lower jaw clip, attached to
each other via a titration screw mechanism located in the
frontal teeth area allowing for precise adjustment of man-
dibular protrusion as well as adjustment of the amount of
vertical opening. This prospective clinical study assesses the
efficacy of this specific custom-made MAD with reduction
of sleep apnea as the main outcome.
Materials and methods
Study population
All patients in this prospective clinical study were diagnosed
with OSA based on a recent polysomnography, with an
apnea–hypopnea index (AHI) of greater than 5 events/h of
sleep [2]. A standard ear, nose, and throat (ENT) clinical
examination was performed in all patients and included a
detailed clinical history, clinical exploration of ear, nose,
and throat with examination of pharyngeal and laryngeal
findings (webbing, size of uvula, soft palate, and tonsils).
On the basis of this ENT examination, the patient was
considered a suitable candidate for MAD treatment and for
this clinical study. Patients were then referred to the dental
sleep professional, who made a full dental examination
including orthopantography. Exclusion criteria were mainly
dental: patients were not judged suitable for MAD treatment
if they suffered from any pre-existing active temporoman-
dibular joint dysfunction, if their dental status or periodontal
health precluded them from wearing an oral appliance, or if
they were fully edentulous [21, 24].
Sixty-one consecutive adult OSA patients (age, 46.7±
9.0 years; male/female ratio, 45/16; AHI, 23.2±15.4 events/
hour of sleep; body mass index (BMI), 27.9±4.1 kg/m²) were
included after written informed consent was provided. Their
age ranged from 26 to 70 years, with a mean age of 46.7 years.
Baseline characteristics of the study population are presented
in Table 1. They started MAD therapy between 1st January
2009 and 1st January 2010.
Ethical approval for this study was obtained from insti-
tutional review boards of the Antwerp University Hospital
(Belgian registration number: B30020110946).
The titratable mandibular advancement device
A custom-made, titratable, commercially available duobloc
MAD with an interconnecting mechanism located in the
frontal teeth area allowing precise adjustment of mandibular
protrusion was selected (RespiDent Butterfly® MRA, Ortho-
dontic Clinics NV, Antwerp, Belgium). The appliance consists
of two clips (Antwerp DentalClip®) that are attached to each
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other via a small screw system located in the frontal teeth area
(Nelissen Titrator®) (Fig. 1). Both clips are interconnected
using the advancement screw, which is mounted horizontally
through the O-ring of the vertical screw of the clip on the
lower jaw up and extending to the eyelet mounted on the clip
in the upper jaw. A safety elastic will prevent this screw from
sliding out the O-ring on unwanted disconnection from the
eyelet. The advancement of the mandible can be titrated
gradually by giving a 360 ° clockwise turn of the horizontal
screw, thereby advancing the mandible 0.5 mm (Fig. 1). The
vertical opening of the MAD, being the distance between the
incisal edges of the upper and lower incisors, can be adjusted
by turning the vertical screw counterclockwise. However, for
this study, it was set as low as possible and patients were
instructed not to change it. The MAD itself “snaps” on the
tooth arches due to the elasticity provided in the appliance by
the stainless steel wires that connect the vestibular and lingual
acrylic embracing parts. Prior to therapy, the maximal protru-
sion was measured three times in each patient and averaged. A
dental registration bite allowed for the transfer of the selected
starting protrusion, being 50% of the maximal protrusion, into
the MAD via the horizontal screw. The fitting as well as the
protrusive start position of the MAD was checked by a qual-
ified dental sleep professional. The patients were instructed to
titrate every 3 days after three to four nights of habituation to
the appliance, until either improvement or resolution of
symptoms like snoring and/or excessive daytime sleepiness
was achieved or until the physiological protrusive limit for the
individual patient was reached.
Objective measurement: polysomnography
Overnight polysomnography (PSG) included the recording
of electroencephalography, right and left electrooculogra-
phy, electromyography of the genioglossus and tibialis an-
terior muscle, electrocardiography, and oxygen saturation
using pulse oximetry with a finger probe. Respiratory vari-
ables were recorded, including nasal airflow by means of an
external thermistor and nasal pressure by using a nasal
pressure cannula. Respiratory effort was measured using
respiratory inductance plethysmography. A microphone
records snoring qualitatively and body position is monitored
using a piëzo-electrical sensor.
The sleep recordings were stored on a computer system
(Brain RT version 1/patch pack 2, OSG, Rumst, Belgium)
and were manually scored thereafter in a standard way by a
qualified sleep technician [2, 25]. An apnea was defined as a
total cessation of airflow during at least 10 s. A hypopnea
was defined as a decrease of airflow of at least 50 % from
the preceding stable airflow in the last 2 min, or a clear
decrease in airflow associated with an oxygen desaturation
of at least 4 % and/or an arousal, during at least 10 s. The
AHI is the average number of apneas and hypopneas per
hour of sleep. Based on the AHI, the following levels of
severity are defined: mild sleep apnea with a score of 5<
AHI≤15, moderate sleep apnea scored 15<AHI≤30, and
severe sleep apnea with AHI>30 events/h of sleep [2].
All patients in this prospective clinical study underwent
two overnight polysomnographic recordings: the first PSG
was performed to diagnose their sleep-related breathing
disorder and will be referred to as the baseline recording.
Once the MAD was optimally titrated relative to resolution
of symptoms or reaching the maximum comfortable limit,
the patient was referred to the sleep laboratory for a follow-
up polysomnography with the MAD in situ. Doing so, the
therapeutic effect of the MAD at the titrated position could
be objectively assessed by comparing the baseline polysom-
nography without MAD with the follow-up PSG with
MAD. The time lag between fitting of the MAD and the
follow-up PSG with MAD in situ was on average 4±
3 months.
Subjective measurements: Epworth Sleepiness Scale
and Visual Analogue Scale for snoring
Epworth Sleepiness Scale (ESS)
The degree of daytime sleepiness can be assessed using a self-
administered questionnaire, called the Epworth Sleepiness
Fig. 1 The RespiDent Butterfly®MAD, consisting of two clips (Antwerp
Dental Clip®), attached to each other allowing adjustment of the mandib-
ular protrusion in the frontal teeth area, as well as vertical positioning
Table 1 Baseline characteristics of the study population
Parameter Mean±SD
Age (years) 46.7±9.0
Gender 73.8 % male
Body mass index, BMI (kg/m²) 27.9±4.1
Weight (kg) 85.2±15.7
Apnea–hypopnea index, AHI (events/h) 23.2±15.4
Epworth Sleepiness Scale, ESS (0–24) 10±5
Visual Analogue Scale for snoring, VAS (0–10) 7±3
Data are expressed as mean±standard deviation (SD) or percentages
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Scale [26]. The ESS is a measure of the probability of falling
asleep in a variety of day life situations. The patients were
asked to rate his or her probability of falling asleep or dozing
off on a scale of 0 to 3 for eight different situations. The ESS
score is the sum of the eight item scores and can range from 0
to 24. Classically, an ESS score higher than 10/24 defines the
presence of excessive daytime sleepiness [26]. Twenty-seven
patients (50.9 %) suffered from excessive daytime sleepiness
(ESS>10/24) before starting MAD treatment.
Visual Analogue Scale (VAS) for snoring
A standard 10-point VAS ranging from 0 to 10 with 0
equaling no snoring and 10 causing the bed partner to leave
the room or sleep separately was used to evaluate the sub-
jective status of snoring, as assessed by the bed partner [27].
Heavy snoring was defined as a VAS snoring index of at
least 7. A decrease of at least three points on VAS for
snoring during treatment with MAD compared to baseline
represents a decrease of one level of snoring severity and
was therefore considered “satisfactory” [21]. To be consid-
ered as an “important” reduction, snoring had to be reduced
to a snoring index that was no longer evaluated as bother-
some, i.e., to a snoring index of ≤3 [21].
Treatment outcome measures
Prior to the start of the study, the following decisions were
made as to the treatment outcomes.
Primary outcome
“Responders” were defined as patients with a reduction in
AHI following MAD treatment of ≥50 % compared to base-
line, and “non-responders” were defined as patients with a
reduction in AHI of <50 % [28]. Treatment success was
defined as a reduction of the AHI to less than 5 or 10/h of
sleep with MAD. Compliance failure was defined as an in-
ability of the patient to continue treatment for whatever reason
mentioned by the patient.
Secondary outcomes
For the subjective secondary outcomes, questionnaires filled
out at baseline and at the time of the follow-up PSG were
analyzed. The VAS for snoring was assessed in the 45
patients who had a bed partner that was able to report the
effect on snoring. To assess patient satisfaction with the
MAD therapy, patients were asked to score their therapy
appreciation at the follow-up visits with 0/10 equaling “very
bad” and 10/10 equaling “very satisfied.” This evaluation
was done at the scheduled follow-up sessions and at the time
of the follow-up PSG.
Patient subjective compliance was assessed at the sched-
uled follow-up visits using a questionnaire, with regard to
how many nights per week the MAD was worn and for how
many hours per night. Regular use was defined by at least
4 h of MAD use on 70 % of the days monitored [29].
Combined primary and secondary outcomes
Success definition including combining primary outcome
with symptomatic reduction in snoring and/or excessive
daytime sleepiness was also included. Complete response
was defined as an “important” reduction of snoring without
excessive daytime sleepiness (ESS<11/24) plus a decrease
in AHI to <5 events/h. Partial response was defined as a
“satisfactory” decrease of snoring without excessive day-
time sleepiness (ESS<11/24) plus a 50 % or greater reduc-
tion in AHI. Treatment failure was defined as ongoing
clinical symptoms and/or a less than 50 % reduction in AHI.
Statistical analysis
Data were statistically analyzed using SPSS software (SPSS
version 17.0, Statistical Package for Social Sciences, SPSS
Inc., Chicago, USA). Normality of distribution was assessed
using QQ plots. All data were assessed as not normal
distributed. Nonparametric Wilcoxon-signed rank test for
paired observations was performed to test the evolution of
the different variables. The significance level was set at 5 %,
p<0.05 was considered significant.
Results
Study population
Polysomnographic re-evaluation with the MAD in situ was
obtained in 57 out of 61 patients: 4 out of the 61 patients
(6.6 %) did not continue their treatment because of teeth
discomfort or pain, excessive salivation, and/or muscle ten-
derness. Weight and BMI of the patients did not change
significantly during MAD therapy.
MAD effect on outcome measures
Primary outcome
At the follow-up polysomnography with the MAD in situ, a
statistically significant improvement was observed regard-
ing AHI. AHI values decreased from 23.4±15.7 events/h at
baseline to 8.9±8.6 events/h with MAD (p<0.01) (Fig. 2).
In four patients (6.6 %), deterioration in apnea severity was
noticed after MAD treatment.
568 Sleep Breath (2013) 17:565–572
The different success definitions with their respective
percentages are summarized in Table 2. According to the
above stated criteria, 42 out of 61 patients (68.8 %) were
found to be “responders” with a reduction in AHI of ≥50 %
following MAD treatment compared to baseline, and 15
patients reacted as “non-responders” with reduction in
AHI of <50 %. Twenty-six patients (42.6 %) met criteria
of treatment success defined as an AHI<5/h with MAD in
situ, and 39 patients (63.9 %) achieved an AHI<10/h with
MAD in situ. More strict criteria of treatment success were
also analyzed: 25 patients (41.0 %) fulfilled success criteria
defined as a reduction in AHI of ≥50 % and AHI<5/h,
whereas in 34 patients (55.7 %), AHI reduced with ≥50 %
and AHI<10/h with MAD in situ. Four out of 61 patients
(6.6 %), two patients with mild sleep apnea and two patients
diagnosed with severe sleep apnea, could not tolerate the
MAD and did not continue their treatment and were defined
as “compliance failures.”
The number of patients in each category of severity
decreased as a result of the MAD treatment and an overall
reduction in the number of patients with OSA was noted,
decreasing from 57 to 31 patients. Responder rates, defined
as a reduction in AHI with MAD of ≥50 % compared to
baseline showed a comparable pattern in mild, moderate, and
severe sleep apnea categories with 66.7 % (16 out of 24
patients), 72.2 % (13 out of 18 patients), and 68.4 % (13 out
of 19 patients), respectively. Success rates for AHI<5/h accord-
ing to these severity categories were 66.7 % (16 out of 24
patients), 33.3 % (6 out of 18 patients) and 22.2 % (4 out of
18 patients) for mild, moderate, and severe sleep apnea, respec-
tively, and for AHI<10/h, we found success percentages of
83.3 % (20 out of 24 patients) for mild sleep apnea
patients, 66.7 % (12 out of 18 patients) for moderate sleep
apnea patients, and 38.9 % (7 out of 18 patients) for severe
sleep apnea.
Secondary outcomes
Epworth Sleepiness Scale A statistically significant (p<0.01)
decrease in daytime sleepiness was observed (n053) follow-
ing MAD treatment, with an ESS at baseline of 10±5 com-
pared to 7±4 with MAD. Twenty-seven patients (50.9 %)
suffered from excessive daytime sleepiness (ESS>10/24) be-
fore starting MAD treatment. In 63.0 % of these patients, the
ESS lowered to a score of ≤10/24, suggesting adequate reso-
lution of excessive daytime sleepiness following MAD
treatment.
Visual Analogue Scale for snoring A statistically significant
decrease in VAS for snoring was observed in all 45 patients
who had a bed partner that was able to report this effect.
VAS decreased from 7±3 at baseline to 3±2 at follow up
PSG (p<0.01). Twenty-eight patients were defined as heavy
snorers, with a VAS snoring index of at least 7 prior to
treatment. In 20 of these 28 heavy snorers (71.4 %), the
subjective score for snoring was reduced to a level below 7.
In general, a decrease of at least three points on VAS for
snoring was noted in 28 out of 45 patients (62.2 %), while
93.3 % of patients reported a reduction in snoring to a VAS
of ≤3 with MAD.
Patient satisfaction On average, patients give their therapy
satisfaction a score of 8/10 (range 4–10). Only one patient
scored the therapy satisfaction below a score of 5/10 be-
cause of a reported pain in the temporomandibular joint.
Subjective compliance Patients reported the use of their
MAD being on average 7±1 nights per week. Forty-eight
patients (87.2 %) claimed to use their MAD every night.
Four patients claimed to use their MAD six nights a week,
two patients were wearing it five nights a week, and one
patient used it only three nights a week. On average, patients
reported using the MAD for 7±1 h per night, with a mini-
mum of 4 h. Fifty-four out of 56 patients (96.4 %) used the
MAD for at least 4 h on 70 % of the days monitored and met
the criteria for regular use.
Fig. 2 Evolution of the apnea–hypopnea index (AHI). Bullets outliers;
*p<0.05
Table 2 Success definitions and results in the present study
Success definition Percentage (%)
Treatment response (decrease of ≥50 % in AHI) 68.8
Treatment success (AHI<5/h) 42.6
Treatment success (AHI<10/h) 63.9
Decrease of ≥50 % in AHI and AHI<5/h 41.0
Decrease of ≥50 % in AHI and AHI<10/h 55.7
Compliance failure 6.6
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Combined primary and secondary outcomes
The evolution of objective and subjective outcome measures
is summarized in Table 3. It was found that the objective as
well as the subjective variables showed a parallel shift
towards less severe OSA in all severity subgroups following
MAD treatment.
Success definition including symptomatic reduction in
snoring and/or excessive daytime sleepiness was also includ-
ed: complete response was reached in 19 patients (31.1 %), 11
patients (18.0 %) were defined as partial responders, and 27
patients (44.3 %) were defined as treatment failure.
Discussion
This prospective clinical study has evaluated a specific
custom-made, titratable MAD with attachments in the front-
al teeth area that allow for progressive titration of the man-
dible. The data demonstrate that this MAD is effective in
treating obstructive sleep apnea by significantly improving
the AHI, subjective snoring, and daytime sleepiness in most
patients diagnosed with OSA.
In the majority of patients (42 out of 61 patients; 68.8 %),
the AHI reduces with ≥50 % with MAD compared to
baseline. This is a response rate comparable to other studies
in the literature where in general 65 % of the patients are
defined as responders, with a ≥50 % reduction in AHI with
the MAD [13]. In the present study, only 4 patients out of 61
patients (6.6 %) were unable to tolerate the MAD and were
defined as compliance failures. This is nevertheless a high
acceptance rate, especially when compared with CPAP,
which is highly efficacious but associated with a relatively
low compliance and acceptance rate [7, 8]: approximately
20 to 40 % will discontinue CPAP treatment after 3 months
[30]. It must, however, be mentioned that the present MAD
study describes relatively short-term results with a mean
follow-up period of 4±3 months. The compliance in con-
tinuing MAD users could be different at long-term follow-
up, but these data are not yet available.
At present, there is no universal agreement upon defini-
tion of a successful treatment outcome with MAD for ob-
structive sleep apnea [13]. This is illustrated by studies that
defined treatment success as a reduction in AHI to below
five, 10, or even 20 events/h of sleep, with or without relief
of concomitant subjective symptoms [13]. In the present
study, treatment success defined as an AHI<5/h with
MAD in situ was achieved in 42.6 and 63.9 % of patients
showing an AHI<10/h with MAD in situ. These are also
comparable high success rates in agreement with other studies
that reported an average of 42 and 52% reaching anAHI<5 or
AHI<10, respectively [13].
The goal of MAD therapy is not only to lower the AHI,
but also to relieve concomitant subjective symptoms in
order to provide a long-term acceptable therapy [21, 31].
Excessive daytime sleepiness and snoring can be socially
disruptive and are often the main complaints of patients and/
or bed partners, respectively. In the present study, 50.9 % of
the patients (27 out of 53) complained of excessive daytime
sleepiness (ESS>10/24), with 11 out of the 15 women
(73.3 %) and 16 out of 38 men (42.1 %) showing a higher
prevalence of hypersomnolence among women. In our
study, in 17 out of the 27 patients (63.0 %) suffering from
excessive daytime sleepiness (ESS>10/24) at baseline, the
Table 3 Evolution of primary
and secondary outcome
measures according to OSA
severity
OSA severity (variables) Baseline PSG (without MAD) Follow-up PSG (with MAD) p value
Mild OSA
AHI 10.0±3.0 4.7±6.2 0.001
VAS 7±3 3±2 <0.001
ESS 9±5 8±4 0.048
Moderate OSA
AHI 20.4±3.6 8.8±6.1 <0.001
VAS 7±2 2±1 0.001
ESS 10±5 8±5 0.023
Severe OSA
AHI 44.2±11.0 14.5±10.6 <0.001
VAS 7±3 3±3 0.009
ESS 11±5 7±5 0.004
All patients
AHI 23.4±15.7 8.9±8.6 <0.001
VAS 7±3 3±3 <0.001
ESS 10±5 7±4 <0.001
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ESS lowered to a score of ≤10, suggesting a decrease of ESS
with the MAD to levels considered as non-pathological.
The efficacy of MAD in the treatment of patients with
severe OSA has been reported in previous studies [32–34].
The present study also demonstrates that the selected MAD
is effective in reducing severity of OSA in most of the
patients with severe OSA (Table 3). Even more, four
patients (23.5 %) with severe OSA who did continue treat-
ment were effectively treated with a final AHI below
5/h sleep with MAD. The success rates, being a reduction
in AHI with MAD of ≥50 % compared to baseline and
continuing treatment, are relatively high with the MAD used
in this study, even for moderate and severe OSA, with
72.2 % for mild OSA and 68.4 % for severe OSA. Despite
these encouraging findings, about one third of patients with
mild and/or severe OSA are still not adequately treated,
indicating that CPAP should be considered a first choice of
treatment in those patients [9].
One specific characteristic of this specific MAD is its
ability to change the vertical opening. Although any oral
appliance will need some interincisal space due to material
requirements, it is still controversial whether an increased
vertical opening could be beneficial for therapy or not [13,
35–37]. It is suggested that raising the bite might be associ-
ated with an aggravation of OSA for some, but not for all
OSA patients [38]. Recent findings by Vroegop et al. [39]
have furthermore emphasized that increasing vertical open-
ing generally tends to result in a negative effect on the
collapsibility of the tongue base. Therefore, the vertical
opening was set as low as possible during this study and
the patients were instructed not to change it in order to
investigate independently the efficacy of the MAD of this
controversial topic.
Up to this date, prediction of treatment success with a
given MAD is still not possible. Furthermore, it has been
reported that the type of oral appliance is one of the factors
that will affect treatment success [19, 20]. Until valid pre-
diction becomes available, evaluation of commercially
available designs of MADs in a clinical environment will
offer a valuable way of studying their power in the treatment
of OSA.
Conclusion
The specific type of custom-made titratable MAD evaluated
allows for a quantifiable titration in both horizontal and
vertical dimensions, of which only the horizontal compo-
nent was explored in the present study. The present results
indicate that within the limits of the present study, this
specific MAD is effective in reducing sleep apnea by low-
ering the AHI, reducing snoring and excessive daytime
sleepiness in a significant way. The MAD has been well
tolerated by patients. Future research can now focus on the
possibilities of having titration options in both vertical and
horizontal dimensions.
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